The role of FDG PET in the management of lymphoma: practical guidelines

Nuclear Medicine Communications

Volumn 28, Issue 5, 2007, Pages 355-357

  Kirby, Anna M ^a   George Mikhaeel, N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Hodgkin lymphoma; Non Hodgkin lymphoma; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG UPTAKE; HODGKIN DISEASE; HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HUMANS; LYMPHOMA; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34147098078     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3280895e34     Document Type: Article

References (2)

1. 18F-FDG PET/CT. J Nucl Med 2005; 46:429-435.
2. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, Goerres GW. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004; 232:823-829.